Cyclin-dependent kinase (CDK) is a key regulator of the cell cycle, controlling progression through various phases by phosphorylating specific target proteins. CDK, in association with cyclins, drives processes such as DNA replication and mitosis, ensuring proper cell division. Dysregulation of CDK activity, often due to mutations in cyclins or other regulatory proteins, is a hallmark of many cancers, leading to uncontrolled cell proliferation. As a result, CDK has become an attractive target for cancer therapy, with CDK inhibitors being developed to halt tumor growth by disrupting cell cycle progression and inducing cell death in cancer cells.